Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0422 Transporter Info
Gene Name SLC5A2
Transporter Name Sodium/glucose cotransporter 2
Gene ID
6524
UniProt ID
P31639
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Dapagliflozin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dapagliflozin inhibits the transportation of Methyl-alpha-D-glucopyranoside by SLC5A2 [5]

Affected Drug/Substrate

 Methyl-alpha-D-glucopyranoside Modulation Type Inhibition

  DT Modulation 2

 Dapagliflozin inhibits the activity of SLC5A2 [6]

Cell System

 Chinese hamster ovary (CHO) cells-SGLT2

  Canagliflozin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Canagliflozin inhibits the activity of SLC5A2 [9]

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisplatin inhibits the expression of SLC5A2 [10]

  Urethane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Urethane inhibits the expression of SLC5A2 [11]

  Cannabidiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cannabidiol increases the expression of SLC5A2 [12]

  Pioglitazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pioglitazone inhibits the activity of SLC5A2 [13]

  Ertugliflozin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ertugliflozin inhibits the activity of SLC5A2 [14]

  Troglitazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Troglitazone induces the activity of SLC5A2 [15]

Drug in Phase 3 Trial

  Bexagliflozin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bexagliflozin inhibits the activity of SLC5A2 [19]

Drug in Phase 1 Trial

  Remogliflozin etabonate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Remogliflozin etabonate inhibits the activity of SLC5A2 [9]

Investigative Drug

  Phlorizin

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phlorizin inhibits the transportation of 2-Deoxyglucose by SLC5A2 [1]

Affected Drug/Substrate

 2-Deoxyglucose Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-SGLT2

  DT Modulation 2

 Phlorizin inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [2]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  DT Modulation 3

 Phlorizin inhibits the transportation of D-glucose by SLC5A2 [3]

Affected Drug/Substrate

 D-glucose Modulation Type Inhibition

  Formononetin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Formononetin inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [4]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  DT Modulation 2

 Formononetin inhibits the activity of SLC5A2 [4]

  Sophoraflavanone G

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sophoraflavanone G inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [4]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  DT Modulation 2

 Sophoraflavanone G inhibits the activity of SLC5A2 [4]

  Sergliflozin A

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sergliflozin A inhibits the transportation of D-glucose by SLC5A2 [3]

Affected Drug/Substrate

 D-glucose Modulation Type Inhibition

  DT Modulation 2

 Sergliflozin A inhibits the activity of SLC5A2 [7]

  Alstiphyllanine D

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Alstiphyllanine D inhibits the transportation of Alpha-D-glucopyranoside by SLC5A2 [8]

Affected Drug/Substrate

 Alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Alstiphyllanine E

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Alstiphyllanine E inhibits the transportation of Alpha-D-glucopyranoside by SLC5A2 [8]

Affected Drug/Substrate

 Alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Alstiphyllanine F

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Alstiphyllanine F inhibits the transportation of Alpha-D-glucopyranoside by SLC5A2 [8]

Affected Drug/Substrate

 Alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Kuraidin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Kuraidin inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [4]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Kurarinone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Kurarinone inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [4]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Kushenol N

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Kushenol N inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [4]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Maackiain

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Maackiain inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [4]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Acerogenin A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acerogenin A inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [2]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Acerogenin B

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acerogenin B inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [2]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

  Acerogenin C

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acerogenin C inhibits the transportation of methyl-alpha-D-glucopyranoside by SLC5A2 [2]

Affected Drug/Substrate

 methyl-alpha-D-glucopyranoside Modulation Type Inhibition

Cell System

 Monkey kidney tissue Fibroblast-like cell lines (COS)1-SGLT2

Natural Product

  Methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methyleugenol inhibits the expression of SLC5A2 [18]

Traditional Medicine

  Jinfukang

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Jinfukang inhibits the expression of SLC5A2 [10]

Environmental toxicant

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Polychlorinated dibenzodioxin affects the expression of SLC5A2 [17]

Herbicide

  Atrazine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Atrazine increases the expression of SLC5A2 [16]
References
1 Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Synthesis and Biological Evaluation. J Med Chem. 2017 Jan 26;60(2):568-579.
2 Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
3 Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem. 2009 Apr 9;52(7):1785-94.
4 Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
5 O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5632-5.
6 Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes. Eur J Med Chem. 2016 May 23;114:89-100.
7 Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. Bioorg Med Chem. 2010 Mar 15;18(6):2178-94.
8 Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
9 Discovery of novel N-beta-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. J Med Chem. 2011 Jan 13;54(1):166-78.
10 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
11 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
12 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321.
13 Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018 Sep 24;9:CD011798.
14 Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017 Oct 3;11:2905-2919.
15 The effect of PPAR agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia. J Endocrinol Invest. 2017 Oct;40(10):1069-1076.
16 Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
17 Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711.
18 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.